Journal of Clinical Oncology, Vol 2, 207-214, Copyright © 1984 by American Society of Clinical Oncology

ARTICLES

Increased therapeutic index of weekly doxorubicin in the therapy of non- small cell lung cancer: a prospective, randomized study

M Valdivieso, MA Burgess, MS Ewer, B Mackay, S Wallace, RS Benjamin, MK Ali, GP Bodey and EJ Freireich

One hundred patients with non-small cell lung cancer were entered into a randomized evaluation of two schedules of doxorubicin combined with ftorafur, cyclophosphamide, and cisplatin (FACP). Doxorubicin was given either weekly at 20 mg/m2, or every three weeks (standard) at 60 mg/m2. Fifty-two patients were randomized to the FACP/weekly doxorubicin arm and 48 patients to the FACP/standard doxorubicin arm. The FACP/weekly doxorubicin regimen was associated with higher complete and partial remission rates (31% versus 19%), longer response duration (median, 33 versus 21 weeks), and longer survival duration for responders (median, 58 versus 50 weeks). These differences were not significant. Less neutropenia (p = 0.01) and less infectious morbidity (p = 0.05) were observed in the FACP/weekly doxorubicin arm. Twenty-eight patients underwent 35 endomyocardial biopsies to assess doxorubicin-induced cardiotoxicity. Sixteen biopsies were performed in 12 patients receiving cumulative doxorubicin doses ranging from 250 to 1,190 mg/m2 within the FACP/weekly doxorubicin arm. Nineteen biopsies were performed in 16 patients receiving cumulative doxorubicin doses ranging from 250 to 540 mg/m2 within the FACP/standard doxorubicin regimen. The FACP/weekly doxorubicin regimen was associated with significantly lower cardiotoxicity scores (p = 0.01). This study indicates that weekly administered doxorubicin is as effective and less cardiotoxic than the standard schedule.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. L. Frei and S. A. Soefje A Review of the Cardiovascular Effects of Oncology Agents Journal of Pharmacy Practice, April 1, 2008; 21(2): 146 - 158. [Abstract] [PDF]

				T K Yeung, K Chakrabarti, D Wilding, and J W Hopewell Modification of doxorubicin-induced cardiotoxicity: manipulation of the dosage schedule Human and Experimental Toxicology, November 1, 2002; 21(11): 607 - 614. [Abstract] [PDF]

				S. E. Lipshultz, A. L. Giantris, S. R. Lipsitz, V. K. Dalton, B. L. Asselin, R. D. Barr, L. A. Clavell, C. A. Hurwitz, A. Moghrabi, Y. Samson, et al. Doxorubicin Administration by Continuous Infusion Is Not Cardioprotective: The Dana-Farber 91-01 Acute Lymphoblastic Leukemia Protocol J. Clin. Oncol., March 15, 2002; 20(6): 1677 - 1682. [Abstract] [Full Text] [PDF]

				M. Sugano, N. K. Egilmez, S. J. Yokota, F.-A. Chen, J. Harding, S. K. Huang, and R. B. Bankert Antibody Targeting of Doxorubicin-loaded Liposomes Suppresses the Growth and Metastatic Spread of Established Human Lung Tumor Xenografts in Severe Combined Immunodeficient Mice Cancer Res., December 1, 2000; 60(24): 6942 - 6949. [Abstract] [Full Text]

				M. I. Koukourakis, S. Koukouraki, A. Giatromanolaki, S. C. Archimandritis, J. Skarlatos, K. Beroukas, J. G. Bizakis, G. Retalis, N. Karkavitsas, and E. S. Helidonis Liposomal Doxorubicin and Conventionally Fractionated Radiotherapy in the Treatment of Locally Advanced Non-Small-Cell Lung Cancer and Head and Neck Cancer J. Clin. Oncol., November 1, 1999; 17(11): 3512 - 3521. [Abstract] [Full Text] [PDF]

				J. Clin. Oncol., July 1, 1999; 17(7): 2293c - 2293. [PDF]

				L. E. Davis Long-Term Complications of Antineoplastic Agents Journal of Pharmacy Practice, January 1, 1991; 4(2): 131 - 150. [PDF]